Fractyl Health rose 11.3% after reporting that REMAIN-1 met its six-month co-primary endpoint, supporting the potential of Revita to help patients maintain weight loss after stopping tirzepatide. The result is encouraging, but the 12-month endpoint remains unreported and is expected in Q1 2027.
- In REMAIN-1, participants lost an average of 18.3% of body weight on tirzepatide before stopping treatment; 308 participants were included in the modified intention-to-treat population.
- At six months, Revita participants retained about 80% of their prior weight loss; the co-primary endpoint was met with a p-value of 0.0023.
- Management reported that the separation from sham widened from months 1 to 6. A post hoc analysis found the best-performing patients, treated over roughly 20 centimeters or more, had less than half the weight regain of sham.
- One in three Revita participants were weight-stable or had lost more weight six months after stopping tirzepatide, and nearly half retained at least 80% of their weight loss.
- The company reported no device- or procedure-related serious adverse events, deaths, or unanticipated adverse device effects. The formal 12-month endpoint is expected in Q1 2027; management also said a de novo application is planned later this quarter.
Community Discussion